DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution (Drug); Concurrent brimonidine 0.2% and 0.5% timolol (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


This study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Adverse Events


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Diagnosis of ocular hypertension or glaucoma

- Patient requires IOP-lowering therapy in both eyes

Exclusion Criteria:

- Uncontrolled medical conditions

- Contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy

Locations and Contacts

Newport Beach, California, United States
Additional Information

Link to Clinical Trial Results

Starting date: November 2005
Last updated: April 1, 2008

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017